Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
10 search results for:

TRK inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-04-2019 | TRK inhibitors | News | Article

    LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors

    Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.

    Published in:
    AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April
  2. 16-08-2022 | WCLC 2022 | Conference coverage | Article

    Entrectinib shows potential as first-line treatment for ROS1 fusion-positive advanced NSCLC

    The latest findings from an integrated analysis of three trials confirm the efficacy of entrectinib for patients with previously treated, locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer, and point to a possible role as a first-line agent in this population.

    Author:
    Lynda Williams
    Published in:
    IASLC World Conference on Lung Cancer 2022; Vienna, Austria: 6–9 August
  3. 25-06-2020 | TRK inhibitors | News | Article
    News in brief

    On-target TRK inhibitor safety profile highlighted

    TRK inhibitor therapy has a “unique” profile of adverse events, suggests a review of lung cancer and other oncology patients attending the Memorial Sloan Kettering Cancer Center in New York, USA.

    Author:
    Lynda Williams
    Published in:
    Ann Oncol 2020; doi:10.1016/j.annonc.2020.05.006
  4. 29-06-2020 | EMA | News | Article
    approvalsWatch

    Entrectinib receives positive decision from EMA

    The announcement includes a second indication, namely for adults with advanced NSCLC harboring ROS1 mutations who have not previously received other ROS1 inhibitors.

  5. 07-08-2019 | EMA | News | Article
    approvalsWatch

    Larotrectinib first tumor-agnostic treatment to get EMA nod

    Specifically, the TRK inhibitor can be given to individuals who have no other treatment options for locally advanced, metastatic, or inoperable disease positive for an NTRK gene fusion.

  6. 02-03-2017 | Liquid biopsy | Review | Article

    Integrating liquid biopsies into the management of cancer

    ESR1 mutations were detected only in patients with oestrogen receptor (ER)-positive disease previously treated with aromatase inhibitors, and were associated with a substantially shorter PFS on subsequent therapy 152 .

    Author:
    Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
  7. 24-02-2017 | Liquid biopsy | Review | Article

    Liquid biopsies come of age: Towards implementation of circulating tumor DNA

    In patients with NSCLC undergoing treatment with EGFR inhibitors, resistance-conferring mutations emerged in plasma ctDNA ahead of clinical progression 170,171 .

    Author:
    Jonathan C. M. Wan, Charles Massie, Javier Garcia-Corbacho, Florent Mouliere, James D. Brenton, Carlos Caldas, Simon Pacey, Richard Baird, Nitzan Rosenfeld
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.